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Abstract
Toxoplasmosis is a well-recognized opportunistic disease in
HIV-infected individuals that is caused by the reactivation of a
previous infection, primarily in the central nervous system,
during profound immunodeficiency. Toxoplasmosis has been
described more rarely in patients with cancer and chemo-
therapy. We report a case of a patient with a history of
chemotherapy for non-Hodgkin lymphoma who developed pain
and progressive paresthesia of the right arm 6 weeks after
remission. Relapsing lymphoma was suspected, and steroid
and radiation treatment were initiated, but the patient died 5
days later due to multiple organ failure. Autopsy revealed
disseminated toxoplasmosis. This case illustrates that toxo-
plasmosis should be suspected in patients with neoplastic
disease, especially lymphomas, who present with unexplained
neurologic, pulmonary, or febrile symptoms during or after
chemotherapy.
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Introduction
Toxoplasmosis is a well-recognized opportunistic disease
in HIV-infected individuals that is caused by the reacti-
vation of a previous infection, primarily in the CNS,
during profound immunodeficiency. Toxoplasmosis has
been described more rarely in patients with cancer and
chemotherapy. We report a fatal case of disseminated
toxoplasmosis in which the patient died 6 weeks after
finishing chemotherapy for non-Hodgkin lymphoma
(NHL).
Case Presentation
A 56-year-old woman with a 3-year history of oligosymptomatic
chronic lymphocytic leukemia experienced a transformation into
a high-grade NHL. Partial remission of the NHL was achieved
after six cycles of chemotherapy with cyclophosphamide, doxo-
rubicin, vincristine, prednisone, and rituximab (R-CHOP). One
year later (January 2007) progressive NHL was treated with
fludarabine and cyclophosphamide without rituximab. Prophy-
lactic cotrimoxazole was administered against Pneumocystis
jiroveci pneumonia (PcP). After six cycles of second line che-
motherapy, clinical and serological remission (tumor marker:
soluble IL-2 receptor) was documented (May 2007).
Six weeks later the patient complained of pain in the right
arm and subsequently developed progressive paresthesia of the
dorsal hand and forearm, including a reduced triceps reflex. The
MRI of the spinal cord showed a solitary lesion in the cervical
region (C5/6) with peripheral contrast enhancement and perifo-
cal edema consistent with relapsing lymphoma of the CNS
(Figure 1). A simultaneous MRI scan of the brain did not reveal
any remarkable abnormalities.
Upon admission, laboratory results were normal, with the
exception of an increased lactate dehydrogenase (LDH) level
(640 U/l; upper limit 429) and a mild renal dysfunction (serum
creatinine level 116 lmol/l). Hematologic analyses revealed
normocytic anemia (hemoglobin 9.9 g/dl) and moderate lym-
phopenia (1,050/ll; normal range 1,500–4,000/ll). These abnor-
malities were stable during the last 3 months before admission
and were interpreted to be lymphoma- and chemotherapy-
related. At this stage, intramedular abscess formation due to
toxoplasmosis or bacterial infection was considered highly un-
likely because of the clinical presentation and the administration
of cotrimoxazole prophylaxis during chemotherapy. Neverthe-
less, toxoplasma PCR of the CSF was performed.
With the presumptive diagnosis of relapsing lymphoma of
the CNS, steroid treatment with methylpredisolone 1 g daily iv
was initiated. Because of progressive neurologic deficits, radia-
tion treatment with 3 Gy at cervical vertebrae 4–7 was also ini-
tiated; 2 days later, the symptoms improved.
On the third day, the patient developed a fever of 39.4 C
without any focal signs, normal inflammatory parameters
(C-reactive protein, leucocytes), and unremarkable chest X-ray
and urinalysis. Radiation therapy was continued, and empiric
antibiotic treatment with meropenem was started. Despite this
measures, the clinical condition deteriorated within 2 days when
hypotension, tachycardia, and respiratory failure with bilateral
pneumonia developed. The patient was admitted to the intensive
care unit (ICU) for pulmonary and circulatory support. Notifi-
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cation of a weakly positive CSF PCR result for Toxoplasma
gondii (446 copies/ml; lower limit of detection 300 copies/ml;
quantitative real time PCR, Institute for Medical Microbiology,
University of Basel) triggered the initiation of additional treat-
ment with pyrimethamine, sulfadiazine, clindamycine, and folinic
acid for toxoplasmosis. However, despite maximal treatment
septic shock with multiple organ failure evolved, and the patient
died 12 h after admission into the ICU.
Autopsy and immunohistochemistry revealed disseminated
toxoplasmosis with T. gondii present in the brain, spinal cord,
heart, and lung (Figure 2). The parasite burden was particularly
high in the brain and spinal cord where single tachyzoites, but
mostly bradyzoites, were detectable in cystic structures in con-
junction with nodules of microglia. The lung showed diffuse
alveolar damage with edema and congestion. Disseminated areas
of necrotizing pneumonia related to toxoplasmosis were mainly
evident in the subpleural areas. Myocardial involvement was
substantiated by several foci of destructive myocarditis associ-
ated with brachyzoites and a cellular infiltrate of lymphocytes.
There was no evidence for persistent or recurrent lymphoma in
the bone marrow, lymph nodes, brain, or any other organs.
Discussion
Toxoplasma gondii is a protozoan parasite that infects up
to one-third of the world’s population. Primary infection
is usually clinically silent, but cervical lymphadenopathy
or ocular disease may be present in immunocompetent
hosts. The parasites usually persist life long in several
organs, and reactivation is mainly suppressed by cellular
immunity [1]. Consequently, toxoplasma-induced organ
disease and death are most prevalent in individuals with
severely compromised cellular immunity, for example,
with HIV-infection or after transplantation [1]. Reacti-
vation and subsequent pathology is usually confined to a
single organ system, and disseminated disease is quite rare
but usually fatal in the absence of specific treatment.
Figure 1. MRI of the spinal cord.
Fig. 2. Histology of the
patient’s autopsy samples:
brain (a), lung (b), and heart (c)
showing bradyzoites of
Toxoplasma gondii (stained
with hematoxylin and eosin). d
Immunohistochemistry of bone
marrow stained for T. gondii
(polyclonal antibody of rabbit;
BioGenex, 1:400; BioGenex
Laboratories, San Ramon, CA).
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However, several studies, particularly those from the
1970s, have reported cases of disseminated toxoplasmosis
during treatment for malignancies, lymphoma, and, in
particular, Hodgkin’s disease [2–4]. Whether newer
treatment regimens for lymphoma or solid malignancies
outside the setting of hematopoietic stem cell transplan-
tation (HSCT) carry an increased risk for toxoplasmosis is
currently not clear. However, several cases of cerebral and
disseminated toxoplasmosis have been reported after flu-
darabine use [5, 6].
Our patient eventually developed rapidly progressive
disseminated toxoplasmosis with multiple organ failure
due to massive involvement of the lung, heart, and CNS.
On admission, there were no signs of heart or lung
involvement since creatine kinase (CK) level (81 U/l,
upper limit of normal < 167 U/l), the electrocardiogram,
and the chest X-ray were unremarkable. Upon ICU
admission, unspecific signs of cardiac disease had evolved,
the CK levels had risen to 761 U/l, and the ECG showed
negative T-waves in I, aVL, and V4–V6. Six weeks after
finishing chemotherapy, the patient presented with neu-
rologic signs (brachial paresis) and a solitary medullar
lesion that was revealed on the MRI scan. At this time,
recurrence of the lymphoma was considered to be the
most likely diagnosis. Consequently, radiation and steroid
treatment were initiated without attempting a confirma-
tory biopsy of the lesion due to the substantial risk for
neurologic sequelae associated with the procedure. Al-
though the MRI scan was also consistent with toxoplas-
mosis or bacterial abscess formation, these differential
diagnoses were also considered unlikely since cotrimox-
azole prophylaxis had been administered until recently
and other factors suggestive of bacterial infection were
absent.
Retrospectively, events were most probably triggered
and accelerated by our stopping the cotrimoxazole pro-
phylaxis after the termination of chemotherapy, unmask-
ing very poor immunocompetence and leading to the first
clinical symptom of toxoplasma reactivation in the CNS.
The clinical presentation with primarily neurologic signs
initially and abscess formation in the CNS strongly suggest
that this was a reactivation process and not a primary
infection with T. gondii. However, since no serological
data for toxoplasma are available, primary toxoplasma
infection cannot be ruled out completely. Our failure to
promptly initiate empiric anti-toxoplasma treatment at
initial presentation was fatal in the context of high-dose
systemic corticosteroid and local radiation treatment
contributing to the fulminant disease course. Specific
treatment was initiated too late to effectively treat the
disseminated disease.
Toxoplasmosis in the setting of solid tumors and
lymphoma and of their treatment is rare, with estimates
ranging from 0.02% in breast cancer up to 3% in patients
with lymphoblastic leukemia [7]. In a review of 128 cases
of cancer-associated toxoplasmosis, Israelski and Rem-
ington recorded 59 patients with Hodgkin lymphomas, 12
with non-Hodgkin lymphomas, 34 with miscellaneous
lymphatic neoplastic diseases, and only 13 with solid tu-
mors [7]. Most cases of toxoplasmosis occurred during
progressive neoplastic disease (only 10% were in stable
remission) and patients were receiving corticosteroids,
alkylating agents, antimetabolites, and/or radiation ther-
apy. Nearly every organ system was involved, particularly
the CNS, heart, and lung.
Our case illustrates that toxoplasmosis should be
suspected—if its diagnosis cannot be excluded – aggres-
sively diagnosed, and treated empirically in patients with
neoplastic disease, especially lymphomas, who present
with unexplained neurologic, pulmonary, or febrile
symptoms during or after chemotherapy. This is particu-
larly relevant for immunosuppressed individuals present-
ing with solitary or multiple CNS lesions. Cotrimoxazole
prophylaxis for PcP is also effective for toxoplasmosis, but
breakthrough disease cannot be fully excluded. Toxo-
plasma serology before the initiation of chemotherapy
may be helpful for risk assessment, whereas a specific
PCR analysis on the CSF is mainly useful if positive, since
the positive predictive value (90–100%) is more reliable
than the negative predictive value (70–80%) [8–10]. A
PCR analysis on the peripheral blood was not performed
in our patient, but such an analysis may be helpful and has
been used in studies of HSCT. However, its diagnostic
performance in cancer patients has not yet been suffi-
ciently validated [11].
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